VOR vs. PRME, ESPR, RGNX, TRML, MBX, ACB, TERN, FHTX, TSHA, and CYRX
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Prime Medicine (PRME), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs.
Prime Medicine (NYSE:PRME) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.
Prime Medicine currently has a consensus target price of $13.13, indicating a potential upside of 343.41%. Vor Biopharma has a consensus target price of $11.36, indicating a potential upside of 728.99%. Given Vor Biopharma's higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Prime Medicine.
Prime Medicine is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Vor Biopharma received 30 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 69.33% of users gave Vor Biopharma an outperform vote while only 61.11% of users gave Prime Medicine an outperform vote.
Prime Medicine has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 23.5% of Prime Medicine shares are held by insiders. Comparatively, 4.7% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Prime Medicine and Prime Medicine both had 1 articles in the media. Prime Medicine's average media sentiment score of 0.00 beat Vor Biopharma's score of -1.00 indicating that Prime Medicine is being referred to more favorably in the media.
Vor Biopharma's return on equity of 0.00% beat Prime Medicine's return on equity.
Summary
Vor Biopharma beats Prime Medicine on 8 of the 14 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 2/22/2025 by MarketBeat.com Staff
